Key figures

	2023	2022	2021	2020	2019
in CHF millions
Net sales	624	725	497	445	525
Gross profit	260	294	161	190	227
Gross profit margin	41.7%	40.6%	32.3%	42.8%	43.2%
EBITDA Chemistry	22	19	20	9	9
EBITDA Paper	37	81	-8	17	55
EBITDA Packaging	43	31	12	28	24
EBITDA Other/Consolidation	–	–	2	1	–
EBITDA	102	131	26	55	88
EBITDA-Marge	16.3%	18.1%	5.2%	12.4%	16.8%
EBIT	83	112	-3¹	25	57
EBIT margin	13.3%	15.5%	-0.5%	5.5%	10.8%
Net result	79	101	-151	47	48
Return on equity ROE	18.9%	28.5%	-38.7%	10.3%	11.4%
Cash flow²	90	129	17	46	80
Cash flow from operating activities	110	98	16	55	61
Capital expenditures for fixed assets	35	34	25	19	23
Free cash flow	92	68	-3	40	40
Total assets	598	666	560	704	703
Shareholders´ equity	436	400	310	472	441
Equity ratio	72.9%	60.0%	55.4%	67.0%	62.8%
Net cash	107	45	-15	-2	-30
Net debt to EBITDA ratio	n.a.	n.a.	0.6	0.0	0.3
Capital employed	325	344	319	468	477
Net operating profit after tax (NOPAT)	70	97	-2	20	49
Return on capital employed (ROCE)	20.9%	29.2%	-0.6%	4.3%	10.3%
Headcount (FTE)	1195	1181	1104	1098	1086

¹ before impairment
² before change in non-financial net working capital

	2023	2022	2021	2020	2019
in CHF
Share price as at 31. December	85.00	78.00	61.00	72.60	79.20
Price-earnings ratio as at 31. December	6.5	4.6	-2.4	9.3	9.8
Earnings per share	13.15	16.83	-25.26	7.82	8.06
Dividend per share	4.00 ¹⁾	4.50	1.30	1.80	1.80
Dividend yield	4.7%	5.8%	2.1%	2.5%	2.3%
Market capitalization (in CHF millions)	510	468	366	436	475

1) Board of Directors´ proposal to Annual General Meeting of 20 March 2024